Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05014568 · ClinicalTrials.gov registry record · Phase 3
Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults
A Phase 3 study of Atopic Dermatitis, sponsored by Organon and.
- Completed
- Registry status
- Phase 3
- Development phase
- 407
- Enrollment target
- 20
- Study locations
NCT05014568 is a Phase 3 study of Atopic Dermatitis that has completed, run by Organon and. The registered enrollment target is 407 participants, below the 607-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (33% lower). The trial reports 20 study locations across 6 states.
The verdict
NCT05014568, a Phase 3 study of Atopic Dermatitis, has completed, sponsored by Organon and.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 407 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a double-blind, randomized, vehicle controlled Phase 3 study to evaluate the efficacy and safety of topical tapinarof cream, 1% compared to vehicle control cream in pediatric and adult subjects with atopic dermatitis.
Conditions Studied
Interventions
- DRUG Vehicle cream
- DRUG tapinarof cream, 1%
Study Locations (20)
California
- Dermavant Investigative Site - Beverly Hills
- Dermavant Investigative Site - Fountain Valley
- Dermavant Investigative Site - Fremont
- Dermavant Investigative Site - Inglewood
- Dermavant Investigative Site - Los Angeles
- Dermavant Investigative Site - Los Angeles
- Dermavant Investigative Site - Mission Viejo
- Dermavant Investigative Site - Sacramento
Florida
- Dermavant Investigative Site - Boca Raton
- Dermavant Investigative Site - Boca Raton
- Dermavant Investigative Site - Brandon
- Dermavant Investigative Site - Coral Gables
- Dermavant Investigative Site - Jacksonville
- Dermavant Investigative Site - Margate
- Dermavant Investigative Site - Miami
- Dermavant Investigative Site - Miami Lakes
Alabama
- Dermavant Investigative Site - Birmingham
Arizona
- Dermavant Investigative Site - Phoenix
Arkansas
- Dermavant Investigative Site - Bryant
District of Columbia
- Dermavant Investigative Site - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 407 participants |
| Start Date | 2021-09-01 |
| Est. Completion | 2023-04-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05014568
The ClinicalTrials.gov registry entry for NCT05014568 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 407 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 607-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (33% lower). The listed sponsor is Organon and, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Vehicle cream is the first listed.
NCT05014568 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT05014568 about?
NCT05014568 is a clinical study titled "Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults". This is a double-blind, randomized, vehicle controlled Phase 3 study to evaluate the efficacy and safety of topical tapinarof cream, 1% compared to vehicle control cream in pediatric and adult subjects with atopic dermatitis.
What is the current status of trial NCT05014568?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 407 participants. The study started on 2021-09-01. Estimated completion is 2023-04-07.
What conditions does trial NCT05014568 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
What interventions are being tested in trial NCT05014568?
The interventions under investigation include: Vehicle cream (DRUG), tapinarof cream, 1% (DRUG).
Who is sponsoring clinical trial NCT05014568?
This trial is sponsored by Organon and, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05014568 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis
RECRUITING · Phase 3
-
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
RECRUITING · Phase 3
-
A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
RECRUITING · Phase 3
-
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 3
-
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis
RECRUITING · Phase 3
-
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.